PAR.AX - Paradigm Biopharmaceuticals Limited

ASX - ASX Delayed Price. Currency in AUD
Currency in AUD

Valuation Measures

Market Cap (intraday) 5791.9M
Enterprise Value 3748.37M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)209.40
Price/Book (mrq)10.22
Enterprise Value/Revenue 3197.89
Enterprise Value/EBITDA 6-77.62

Trading Information

Stock Price History

Beta (5Y Monthly) 0.93
52-Week Change 3274.55%
S&P500 52-Week Change 321.38%
52 Week High 34.5000
52 Week Low 31.0840
50-Day Moving Average 33.7514
200-Day Moving Average 32.8543

Share Statistics

Avg Vol (3 month) 3862.16k
Avg Vol (10 day) 3690.69k
Shares Outstanding 5194.48M
Float 140.57M
% Held by Insiders 1N/A
% Held by Institutions 1N/A
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Jun 30, 2019
Most Recent Quarter (mrq)Dec 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-255.17%

Management Effectiveness

Return on Assets (ttm)-11.85%
Return on Equity (ttm)-33.11%

Income Statement

Revenue (ttm)3.78M
Revenue Per Share (ttm)0.02
Quarterly Revenue Growth (yoy)2,835.20%
Gross Profit (ttm)2.98M
EBITDA -9.64M
Net Income Avi to Common (ttm)-16.33M
Diluted EPS (ttm)-0.0960
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)73.63M
Total Cash Per Share (mrq)0.37
Total Debt (mrq)930.26k
Total Debt/Equity (mrq)1.17
Current Ratio (mrq)66.64
Book Value Per Share (mrq)0.40

Cash Flow Statement

Operating Cash Flow (ttm)-10.29M
Levered Free Cash Flow (ttm)-7.17M